ClinicalTrials.gg
CompletedNCT03414983CheckMate 9X8Updated Nov 18, 2023Results posted

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

A Phase 2/3 interventional study of Nivolumab and Oxaliplatin in Colorectal Cancer, sponsored by Bristol-Myers Squibb. Completed at 49 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.

Enrollment
7th of 38
196 · median 49
Started
2018
with 3 others
Phase 2/3
Only one
of the 38
Registered
8th of 38
by date
Lead sponsor
6 of 38
Bristol-Myers Squibb

Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 7th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 8th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing nivolumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed colorectal cancer, not amenable to curative resection
  • No prior chemotherapy for metastatic colorectal cancer
  • Performance Status of 0-1
  • Ability to provide adequate tissue sample

Exclusion criteria

Exclusion Criteria:

  • Patients with medical history, including disease, cardiovascular disease, hepatic disease or bleeding disorders
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Any positive test result for virus or virus indicating presence of virus

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Arm A

    Nivo + SOC

    Biological: Nivolumab · Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Bevacizumab

  • Active comparator
    Arm B

    SOC

    Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Bevacizumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Calcium Folinate

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

    Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per BICR and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression per BICR will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per BICR will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.

    Time frame: From randomization to up to the date of the first documented progression (up to 16 months)

Secondary outcomes

  1. Progression Free Survival (PFS) Per Investigator Assessment

    Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by Investigator Assessment, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per Investigator Assessment and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per Investigator Assessment will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.

    Time frame: From randomization up to the date of the first documented progression (up to approximately 44 months)

  2. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

    ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by BICR per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

    Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

  3. Objective Response Rate (ORR) Per Investigator Assessment

    ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by tumor assessments by the Investigator per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

    Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

  4. Duration of Response (DoR) Per Blinded Independent Central Review (BICR)

    Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the BICR based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

    Time frame: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)

  5. Duration of Response (DoR) Per Investigator Assessment

    Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the investigator based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

    Time frame: From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)

  6. Time to Objective Response Per Blinded Independent Central Review (BICR)

    Time to objective response (TTR) is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by BICR. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.

    Time frame: From the randomization date up to the date of the first confirmed CR or PR (up to approximately 44 months)

  7. Time to Objective Response Per Investigator Assessment

    TTR is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by investigator. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.

    Time frame: From the randomization date up to the date of the first confirmed CR or PR (up to 44 months)

  8. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

    Time frame: From the date of randomization up to the date of death (up to 44 months)

  9. Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose to 30 days post last dose (up to 45 months)

  10. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose to 30 days post last dose (up to 45 months)

  11. Number of Participants Experiencing Death

    The number of participants who died during the treatment period

    Time frame: From first dose up to 6 weeks post last dose (up to 46 months)

  12. Number of Participants With Laboratory Abnormalities in Specific Liver Tests

    The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

    Time frame: From first dose up to 30 days post last dose (up to 45 months)

  13. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

    Time frame: From first dose up to 30 days post last dose (up to 45 months)

  14. Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)

    Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

    Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

  15. Disease Control Rate (DCR) Per Investigator

    Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

    Time frame: From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)

07

Results

Posted Feb 25, 2022

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Started12768
Completed12362
Not completed46
Withdrew: Other reasons10
Withdrew: Participant no longer meets study criteria23
Withdrew: Participant withdrew consent13
Treatment
Participant flow — Treatment
MilestoneArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Started12362
Completed90
Not completed11462
Withdrew: Participant withdrew consent43
Withdrew: Participant request to discontinue study treatment810
Withdrew: Adverse event unrelated to study drug52
Withdrew: Death01
Withdrew: Study drug toxicity105
Withdrew: Disease progression7529
Withdrew: Not reported10
Withdrew: Other reasons32
Withdrew: Poor/non-compliance20
Withdrew: Maximum clinical benefit59
Withdrew: Lost to follow-up01
Withdrew: Administrative reasons by sponsor10

Outcome measures

PrimaryProgression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by BICR (per RECIST 1.1), or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per BICR and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression per BICR will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per BICR will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.

Time frame:
From randomization to up to the date of the first documented progression (up to 16 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)11.86 (8.94 to 15.70)11.93 (10.09 to 12.19)
Statistical analysis
  • Arm A: NIV+mFOLFOX+BEV vs Arm B: mFOLFOX+BEV · Log Rank · p = 0.3022 (Stratified regular log-rank test) · Hazard ratio (hr): 0.81 · 80% CI 0.61 to 1.07Stratified Cox proportional hazard model
  • Arm A: NIV+mFOLFOX+BEV vs Arm B: mFOLFOX+BEV · Log Rank · p = 0.3022 (Stratified regular log-rank test) · Hazard ratio (hr): 0.81 · 95% CI 0.53 to 1.23Stratified Cox proportional hazard model
SecondaryProgression Free Survival (PFS) Per Investigator Assessment

Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by Investigator Assessment, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression per Investigator Assessment and who did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the date of the last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who die without a reported prior progression per Investigator Assessment will be considered to have progressed on the date of death. Participants who did not have any baseline or post baseline tumor assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date.

Time frame:
From randomization up to the date of the first documented progression (up to approximately 44 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Investigator Assessment
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Progression Free Survival (PFS) Per Investigator Assessment13.77 (11.53 to 15.70)12.19 (10.25 to 14.06)
Statistical analysis
  • Arm A: NIV+mFOLFOX+BEV vs Arm B: mFOLFOX+BEV · Hazard ratio (hr): 0.80 · 95% CI 0.54 to 1.19Stratified Cox proportional hazard model
SecondaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by BICR per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

Time frame:
From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
Percentage of ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)60.6 (51.6 to 69.2)45.6 (33.5 to 58.1)
SecondaryObjective Response Rate (ORR) Per Investigator Assessment

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response designation as determined by tumor assessments by the Investigator per RECIST 1.1, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

Time frame:
From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Investigator Assessment
Percentage of participantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Objective Response Rate (ORR) Per Investigator Assessment60.6 (51.6 to 69.2)52.9 (40.4 to 65.2)
SecondaryDuration of Response (DoR) Per Blinded Independent Central Review (BICR)

Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the BICR based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

Time frame:
From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)
Reported as:
Median · Months
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)12.88 (9.00 to 14.72)9.26 (7.49 to 11.30)
SecondaryDuration of Response (DoR) Per Investigator Assessment

Duration of objective response (DoR) is defined as the time between the date of first confirmed complete response (CR) or partial response (PR) to the date of the first documented tumor progression as assessed by the investigator based on RECIST 1.1 criteria or death due to any cause, whichever occurs first. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm.

Time frame:
From randomization up to the date of the first documented progression (per RECIST 1.1) or death due to any cause, whichever occurs first (up to 44 months)
Reported as:
Median · Months
Duration of Response (DoR) Per Investigator Assessment
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Duration of Response (DoR) Per Investigator Assessment12.48 (8.87 to 16.72)11.07 (9.43 to 17.31)
SecondaryTime to Objective Response Per Blinded Independent Central Review (BICR)

Time to objective response (TTR) is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by BICR. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.

Time frame:
From the randomization date up to the date of the first confirmed CR or PR (up to approximately 44 months)
Reported as:
Median · Months
Time to Objective Response Per Blinded Independent Central Review (BICR)
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Time to Objective Response Per Blinded Independent Central Review (BICR)2.83 ± 1.512.83 ± 1.45
SecondaryTime to Objective Response Per Investigator Assessment

TTR is defined as the time from the randomization date to the date of the first confirmed complete response (CR) or partial response (PR) as assessed by investigator. PR is defined as at least a 30% decrease in the sum of diameters of target lesions. CR is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. TTR is derived for responders only.

Time frame:
From the randomization date up to the date of the first confirmed CR or PR (up to 44 months)
Reported as:
Median · Months
Time to Objective Response Per Investigator Assessment
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Time to Objective Response Per Investigator Assessment2.83 ± 2.512.83 ± 1.34
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

Time frame:
From the date of randomization up to the date of death (up to 44 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Overall Survival (OS)30.52 (25.20 to 39.39)31.77 (24.38 to 38.70)
SecondaryNumber of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose to 30 days post last dose (up to 45 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Number of Participants With Adverse Events (AEs)12261
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose to 30 days post last dose (up to 45 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Number of Participants With Serious Adverse Events (SAEs)5720
SecondaryNumber of Participants Experiencing Death

The number of participants who died during the treatment period

Time frame:
From first dose up to 6 weeks post last dose (up to 46 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Death
ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Number of Participants Experiencing Death8742
SecondaryNumber of Participants With Laboratory Abnormalities in Specific Liver Tests

The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

Time frame:
From first dose up to 30 days post last dose (up to 45 months)
Reported as:
Number · Participants
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
ALT OR AST > 3XULN166
ALT OR AST > 5XULN72
ALT OR AST > 10XULN20
ALT OR AST > 20XULN00
TOTAL BILIRUBIN > 2XULN01
ALP > 1.5XULN3920
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY21
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS21
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY01
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS01
SecondaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

Time frame:
From first dose up to 30 days post last dose (up to 45 months)
Reported as:
Number · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
TSH > ULN4523
TSH > ULN WITH TSH <= ULN AT BASELINE3716
TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN202
TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN119
TSH > ULN WITH FT3/FT4 TEST MISSING1412
TSH < LLN253
TSH < LLN WITH TSH >= LLN AT BASELINE223
TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN130
TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN82
TSH < LLN WITH FT3/FT4 TEST MISSING41
SecondaryDisease Control Rate (DCR) Per Blinded Independent Central Review (BICR)

Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

Time frame:
From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)
Percentage of participantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Disease Control Rate (DCR) Per Blinded Independent Central Review (BICR)91.3 (85.0 to 95.6)83.8 (72.9 to 91.6)
SecondaryDisease Control Rate (DCR) Per Investigator

Disease Control Rate (DCR) is defined as the percentage of participants whose Best Overall Response (BOR) is complete response (CR) or partial response (PR) or stable disease (SD). CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.

Time frame:
From the date of randomization up to the date of objectively documented progression or the date of subsequent anticancer therapy, whichever occurs first (up to approximately 44 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per Investigator
Percentage of participantsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Disease Control Rate (DCR) Per Investigator85.8 (85.0 to 95.6)77.9 (66.2 to 87.1)
Post-hocProgression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection

PFS is the time from randomization to the date of first documented progression, as determined by BICR, or death due to any cause, whichever occurs first. Baseline tumor assessment is defined as tumor scans prior to or on randomization date. Participants who did not have documented progression and did not die or participants who started any subsequent anti-cancer therapy without a prior reported progression were censored on date of last tumor assessment on or prior to initiation of the subsequent anticancer therapy, if any. Participants who died without prior progression were considered to have progressed on the date of death. Participants who did not have any baseline assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) were censored at the randomization date. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date.

Time frame:
From randomization to up to the date of the first documented progression (up to 44 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection
MonthsArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection11.99 (9.99 to 15.74)12.02 (10.25 to 13.37)
Statistical analysis
  • Arm A: NIV+mFOLFOX+BEV vs Arm B: mFOLFOX+BEV · Log Rank · p = 0.5041 (Stratified regular log-rank test) · Hazard ratio (hr): 0.88 · 80% CI 0.67 to 1.15Stratified Cox proportional hazard model
  • Arm A: NIV+mFOLFOX+BEV vs Arm B: mFOLFOX+BEV · Log Rank · p = 0.5041 (Stratified regular log-rank test) · Hazard ratio (hr): 0.88 · 95% CI 0.58 to 1.32Stratified Cox proportional hazard model

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 58 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 45 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: NIV+mFOLFOX+BEV89/127 (70.1%)67/123 (54.5%)122/123 (99.2%)
Arm B: mFOLFOX+BEV47/68 (69.1%)25/62 (40.3%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
ColitisGastrointestinal disorders9/1230/62
Febrile neutropeniaBlood and lymphatic system disorders6/1231/62
SepsisInfections and infestations6/1231/62
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/1231/62
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/1232/62
Abdominal painGastrointestinal disorders5/1233/62
PneumoniaInfections and infestations4/1230/62
Intestinal perforationGastrointestinal disorders1/1232/62
DeathGeneral disorders2/1232/62
DiarrhoeaGastrointestinal disorders3/1230/62
Most frequent other events
Showing 10 of 87
Most frequent other events
EventArm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEV
NauseaGastrointestinal disorders83/12335/62
FatigueGeneral disorders73/12338/62
DiarrhoeaGastrointestinal disorders74/12320/62
Peripheral sensory neuropathyNervous system disorders45/12328/62
Neuropathy peripheralNervous system disorders54/12321/62
ConstipationGastrointestinal disorders52/12321/62
VomitingGastrointestinal disorders49/12313/62
Decreased appetiteMetabolism and nutrition disorders47/12316/62
NeutropeniaBlood and lymphatic system disorders45/12314/62
Abdominal painGastrointestinal disorders40/12319/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEVTotal
Mean56.8 ± 13.357.2 ± 11.456.9 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEVTotal
Female571976
Male7049119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEVTotal
Hispanic or Latino7916
Not Hispanic or Latino10853161
Unknown or Not Reported12618
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: NIV+mFOLFOX+BEVArm B: mFOLFOX+BEVTotal
White9657153
Black or African American8210
Asian15520
Other639
Not Reported213
08

Study locations

49 sites
  • Uab Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • Local Institution - 0004
    Los Angeles, California 90033, United States
  • Local Institution - 0010
    Aurora, Colorado 80045, United States
  • Local Institution - 0027
    Denver, Colorado 80218, United States
  • Local Institution - 0020
    New Haven, Connecticut 06520, United States
  • Local Institution - 0039
    Miami, Florida 33176, United States
  • Local Institution - 0047
    Saint Petersburg, Florida 33705, United States
  • Local Institution - 0033
    Arlington Heights, Illinois 60005, United States
  • Local Institution - 0044
    Indianapolis, Indiana 46260, United States
  • Local Institution - 0021
    Bethesda, Maryland 20817, United States
  • Local Institution - 0003
    Boston, Massachusetts 02114, United States
  • Local Institution - 0049
    Boston, Massachusetts 02114, United States
  • Local Institution - 0052
    Boston, Massachusetts 02114, United States
  • Local Institution - 0053
    Boston, Massachusetts 02114, United States
  • Local Institution - 0035
    Minneapolis, Minnesota 55404, United States
  • Local Institution - 0002
    Rochester, Minnesota 55905, United States
  • Local Institution - 0032
    Papillion, Nebraska 68046, United States
  • Local Institution - 0029
    Henderson, Nevada 89074, United States
  • Local Institution - 0031
    Johnson City, New York 13790, United States
  • Local Institution - 0046
    New York, New York 10016, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28262, United States
  • Local Institution - 0038
    Portland, Oregon 97227, United States
  • Local Institution - 0005
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0024
    Pittsburgh, Pennsylvania 15212, United States
  • Local Institution - 0023
    Sioux Falls, South Dakota 57104, United States
  • Erlanger Oncology & Hematology - Univ. of TN
    Chattanooga, Tennessee 37403, United States
  • Local Institution - 0019
    Nashville, Tennessee 37203, United States
  • Local Institution - 0026
    Bedford, Texas 76022, United States
  • Local Institution - 0034
    Dallas, Texas 75246, United States
  • Local Institution - 0037
    Fort Worth, Texas 76104, United States
  • Local Institution - 0040
    San Antonio, Texas 78217, United States
  • Local Institution - 0036
    Tyler, Texas 75702, United States
  • Local Institution - 0025
    Richmond, Virginia 23229, United States
  • Local Institution - 0028
    Roanoke, Virginia 24014, United States
  • Local Institution - 0006
    Madison, Wisconsin 53705, United States
  • Local Institution - 0017
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0015
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0014
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0048
    Montreal, Quebec H2X 1P1, Canada
  • Local Institution - 0012
    Quebec City, Quebec G1J 1Z4, Canada
  • Local Institution - 0013
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0016
    Trois-Rivieres, Quebec G8Z 3R9, Canada
  • Local Institution - 0055
    Nagoya, Aichi 4648681, Japan
  • Local Institution - 0051
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution - 0050
    Sunto-gun, Shizuoka 4118777, Japan
  • Local Institution - 0009
    San Juan, 00927, Puerto Rico
  • Local Institution - 0043
    Barcelona, 08035, Spain
  • Local Institution - 0042
    Madrid, 28034, Spain
  • Local Institution - 0041
    Majadahonda - Madrid, 28222, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Feb 2021, 35 months.

Results were first posted in Feb 2022, 1 year after primary completion.

Of 36 phase 2/3 interventional studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 105. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Jan 30, 2018
StartActual
Feb 20, 2018
Primary completionActual
Feb 1, 2021
CompletionActual
Dec 28, 2022
Results first posted
Feb 25, 2022
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03414983
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
Feb 20, 2018
Primary completion
Feb 1, 2021
Completion
Dec 28, 2022
Results posted
Feb 25, 2022
Last update
Nov 18, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Suibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion